BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 11472341)

  • 21. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen.
    Schaap N; Schattenberg A; Bär B; Preijers F; Geurts van Kessel A; van der Maazen R; de Boo T; de Witte T
    Br J Haematol; 1997 Sep; 98(3):750-9. PubMed ID: 9332335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
    Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-leukemia reactions after bone marrow transplantation.
    Horowitz MM; Gale RP; Sondel PM; Goldman JM; Kersey J; Kolb HJ; Rimm AA; Ringdén O; Rozman C; Speck B
    Blood; 1990 Feb; 75(3):555-62. PubMed ID: 2297567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
    Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
    Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.
    Marks DI; Hughes TP; Szydlo R; Kelly S; Cullis JO; Schwarer AP; Mackinnon S; Apperley J; Barrett AJ; Hows JM
    Br J Haematol; 1992 Jul; 81(3):383-90. PubMed ID: 1390211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
    Alimoghaddam K; Ghaffari H; Foroughi F; Chardouli B; Sanaat Z; Bahar B; Mousavi A; Iravani M; Ghavamzadeh A
    Arch Iran Med; 2006 Apr; 9(2):99-103. PubMed ID: 16649348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.
    Nimer SD; Giorgi J; Gajewski JL; Ku N; Schiller GJ; Lee K; Territo M; Ho W; Feig S; Selch M
    Transplantation; 1994 Jan; 57(1):82-7. PubMed ID: 8291119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
    Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Murray C; Gonin R; Ritz J
    Blood; 1994 Aug; 84(3):964-71. PubMed ID: 8043878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Fujimori Y; Takatsuka H; Takemoto Y; Hara H; Okamura H; Nakanishi K; Kakishita E
    Br J Haematol; 2000 Jun; 109(3):652-7. PubMed ID: 10886219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.